{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:07:57Z","timestamp":1767650877966},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1097\/rhu.0b013e318190dd88","type":"journal-article","created":{"date-parts":[[2008,11,28]],"date-time":"2008-11-28T08:20:04Z","timestamp":1227860404000},"page":"353-356","source":"Crossref","is-referenced-by-count":47,"title":["Biologic Therapy(TNF-\u03b1 Antagonists)-Induced Psoriasis"],"prefix":"10.1097","volume":"14","author":[{"given":"Raquel","family":"Cuchacovich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen G.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zia","family":"Virk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis R.","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210207","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0002-9629(15)40418-5","article-title":"Insights into the pathogenesis of psoriasis and psoriatic arthritis.","volume":"316","author":"Espinoza","year":"1998","journal-title":"Am J Med Sci"},{"key":"R2-9-20210207","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.22489","article-title":"Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options.","volume":"56","author":"Turkiewicz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R3-9-20210207","first-page":"374","article-title":"Toll-like receptor 2 expression is up-regulated in antigen presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity.","volume":"34","author":"Candia","year":"2007","journal-title":"J Rheumatol"},{"key":"R4-9-20210207","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI200318986","article-title":"Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model.","volume":"112","author":"Villadsen","year":"2003","journal-title":"J Clin Invest"},{"key":"R5-9-20210207","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.","volume":"204","author":"Zaba","year":"2007","journal-title":"J Exp Med"},{"key":"R6-9-20210207","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R7-9-20210207","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000095033","article-title":"Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview.","volume":"213","author":"Pirard","year":"2006","journal-title":"Dermatology"},{"key":"R8-9-20210207","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/ard.2006.054833","article-title":"Tumor necrosis factor inhibition causing psoriasis? A more plausible explanation exists.","volume":"65","author":"Carter","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R9-9-20210207","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2006.059261","article-title":"A medical conundrum: onset of psoriasis in patients receiving anti-tumor necrosis factor agents.","volume":"65","author":"Ritchlin","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R10-9-20210207","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/ard.2005.037424","article-title":"New onset or exacerbation of psoriatic skin lesions in patients with defined rheumatoid arthritis receiving tumor necrosis factor alpha antagonists.","volume":"65","author":"Kary","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"R11-9-20210207","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/j.1365-4632.2006.03041.x","article-title":"Anti-TNF alpha induced psoriasis: case report of an unusual adverse event.","volume":"45","author":"Aslanidis","year":"2006","journal-title":"Intern J Dermatol"},{"key":"R12-9-20210207","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.rhu.0000240045.16855.39","article-title":"The appearance of pustular psoriasis during antitumor necrosis factor therapy.","volume":"12","author":"Pereira Goncalves","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"R13-9-20210207","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor alpha antagonist therapy: a case series.","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"key":"R14-9-20210207","first-page":"223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatological conditions.","volume":"143","author":"deGannes","year":"2007","journal-title":"Arch Dermatol"},{"key":"R15-9-20210207","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side effects in patients with rheumatic diseases during application of tumor necrosis factor antagonists.","volume":"156","author":"Lee","year":"2007","journal-title":"Br J Dermatol"},{"key":"R16-9-20210207","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1001\/archderm.143.2.270","article-title":"Onset of psoriasis during treatment with TNF-(alpha) antagonists: a report of three cases.","volume":"143","author":"Ubriani","year":"2007","journal-title":"Arch Dermatol"},{"key":"R17-9-20210207","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.semarthrit.2007.05.004","article-title":"The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review.","volume":"37","author":"Grinblat","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"R18-9-20210207","first-page":"659","article-title":"Severe bout of cutaneous psoriasis in a patient with psoriatic arthritis undergoing treatment with infliximab.","volume":"25","author":"Uriarte Itzazalaia","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"R19-9-20210207","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/RHU.0b013e31816b95bc","article-title":"Psoriasis induced by anti-TNF probably not so uncommon.","volume":"14","author":"Bosch","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R20-9-20210207","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/RHU.0b013e31816b95d4","article-title":"Onset of psoriasis induced by infliximab.","volume":"14","author":"Bal","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R21-9-20210207","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/RHU.0b013e31816b95ea","article-title":"Anti-TNF agents inducing psoriasis: a recognized adverse effect.","volume":"14","author":"Scheinberg","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"R22-9-20210207","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine"},{"key":"R23-9-20210207","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.jidsymp.5650037","article-title":"Mechanisms of action of etanercept in psoriasis.","volume":"12","author":"Tan","year":"2007","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R24-9-20210207","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2133.2005.06648.x","article-title":"Cytokine profiles during infliximab monotherapy in psoriatic arthritis.","volume":"153","author":"Mastroianni","year":"2005","journal-title":"Br J Dermatol"},{"key":"R25-9-20210207","first-page":"454","article-title":"The role of lesional T cells in recalcitrant psoriasis during infliximab therapy.","volume":"15","author":"Bovenschen","year":"2005","journal-title":"Eur J Dermatol"},{"key":"R26-9-20210207","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/archderm.143.2.233","article-title":"The Yin and Yang of TNF alpha inhibition.","volume":"143","author":"Fiorentino","year":"2007","journal-title":"Arch Dermatol"},{"key":"R27-9-20210207","first-page":"107","article-title":"Extensive psoriasis induced by pegylated interferon-alpha-2b treatment for chronic hepatitis B.","volume":"15","author":"Ketikoglou","year":"2005","journal-title":"Eur J Dermatol"},{"key":"R28-9-20210207","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid pre-dendritic cells initiate psoriasis through interferon alpha production.","volume":"202","author":"Nestle","year":"2005","journal-title":"J Exp Med"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00124743-200812000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:02:02Z","timestamp":1618038122000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-200812000-00009"}},"subtitle":["A Cytokine Imbalance Between TNF-\u03b1 and IFN-\u03b1?"],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e318190dd88","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}